| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 24,060 | 23,695 |
| Effect of exchange rate changes on cash and cash equivalents | 216 | 99 |
| Net increase (decrease) in cash and cash equivalents | 28,589 | 24,678 |
| Cash and cash equivalents at beginning of period | 11,813 | - |
| Cash and cash equivalents at end of period | 40,402 | - |
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)